The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.
about
New insight into the mechanisms underlying the function of the incretin hormone glucagon-like peptide-1 in pancreatic β-cells: the involvement of the Wnt signaling pathway effector β-cateninCrystal structure of the incretin-bound extracellular domain of a G protein-coupled receptorIncretin effect of Urena lobata leaves extract on structure and function of rats islet β-cells.Long-term impact of liraglutide, a glucagon-like peptide-1 (GLP-1) analogue, on body weight and glycemic control in Japanese type 2 diabetes: an observational studyShort-term effects of liraglutide on visceral fat adiposity, appetite, and food preference: a pilot study of obese Japanese patients with type 2 diabetes.Rationale for dipeptidyl peptidase 4 inhibitors: a new class of oral agents for the treatment of type 2 diabetes mellitus.Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation.Role of MAPK in apolipoprotein CIII-induced apoptosis in INS-1E cells.Exendin-4 Promotes Survival of Mouse Pancreatic β-Cell Line in Lipotoxic Conditions, through the Extracellular Signal-Related Kinase 1/2 PathwayThe role of nitric oxide synthase in post-operative hyperglycaemia.Evidence-based practice use of incretin-based therapy in the natural history of diabetes.GLP-1 Receptor Agonists: Practical Considerations for Clinical Practice.GLP-1(28-36) improves β-cell mass and glucose disposal in streptozotocin-induced diabetic mice and activates cAMP/PKA/β-catenin signaling in β-cells in vitro.GLP-1/Exendin-4 induces β-cell proliferation via the epidermal growth factor receptorAngiotensin II type 1 receptor antagonists prevent glucose-induced increases in islet blood flow in rats.Effect of glycosylation on biodistribution of radiolabeled glucagon-like peptide 1.Functional association of the N-terminal residues with the central region in glucagon-related peptides.
P2860
Q26823824-89CD1CD3-3842-4DC7-97F8-3BD090568B1DQ27647464-B2C5FA3B-E282-4C64-AEBC-905BE093B5DFQ33896508-27377EAF-7098-467F-A471-4C48CD42580EQ34202922-ED51118E-4851-42C8-8EA4-39CDD03FDE01Q35677365-565B694A-4E6C-4E97-8090-2176755C36FDQ36693199-1F8B3C98-FABA-4384-AB21-79D787D170DBQ36758200-EE6DDE60-1609-4476-BDCB-E71C134E4A1FQ37109991-4A113A68-E8D6-42F7-9069-9A8F56C67596Q37253148-2B5534F3-45BE-49DD-B377-C782AEEA7D71Q37868424-E6426822-A61A-4924-B3C6-05C11809929DQ38219482-AAFC7EA3-3BF1-4CE2-B2E6-69AB90087879Q38602769-D93EF21A-F6D0-4F44-8928-7C1F4EB1270CQ39168828-8ECCCFCC-F106-4D0F-B501-C8279D3C7F85Q41490586-75B52BBB-3F51-40B9-B4DF-186352E4DCE1Q46307708-1558F036-2F52-4B56-82CE-694A6E7FAF47Q46922700-7E397CBF-DA1D-40E6-A22F-07D5C6D76284Q53241623-CD511348-43CB-42B3-A065-80979AB0A2B7
P2860
The incretin approach for diabetes treatment: modulation of islet hormone release by GLP-1 agonism.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年学术文章
@wuu
2004年学术文章
@zh-cn
2004年学术文章
@zh-hans
2004年学术文章
@zh-my
2004年学术文章
@zh-sg
2004年學術文章
@yue
2004年學術文章
@zh
2004年學術文章
@zh-hant
name
The incretin approach for diab ...... mone release by GLP-1 agonism.
@ast
The incretin approach for diab ...... mone release by GLP-1 agonism.
@en
type
label
The incretin approach for diab ...... mone release by GLP-1 agonism.
@ast
The incretin approach for diab ...... mone release by GLP-1 agonism.
@en
prefLabel
The incretin approach for diab ...... mone release by GLP-1 agonism.
@ast
The incretin approach for diab ...... mone release by GLP-1 agonism.
@en
P1433
P1476
The incretin approach for diab ...... mone release by GLP-1 agonism.
@en
P2093
Cathrine Orskov
P304
P356
10.2337/DIABETES.53.SUPPL_3.S197
P407
P478
53 Suppl 3
P577
2004-12-01T00:00:00Z